Hyperactivation of NF-κB signaling in splicing factor mutant myelodysplastic syndromes and therapeutic approaches
Open Access
- 9 October 2024
- journal article
- Published by Elsevier in Advances in Biological Regulation
- Vol. 95, 101055
Abstract
No abstract availableKeywords
Funding Information
- Leukaemia UK (PG17/002)
- Blood Cancer UK (13042)
- Blood Cancer UK (19004)
This publication has 93 references indexed in Scilit:
- The Interleukin‐1 Receptor–Associated Kinase 4 Inhibitor PF‐06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical TrialArthritis & Rheumatology, 2021
- Spliceosomal factor mutations and mis-splicing in MDSBest Practice & Research Clinical Haematology, 2020
- Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene MutationsCancer Cell, 2018
- NF-κB and the Transcriptional Control of Inflammation2018
- Physiologic Expression of Sf3b1 K700E Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome ModulationCancer Cell, 2016
- Unraveling Myelodysplastic Syndromes: Current Knowledge and Future DirectionsCurrent Oncology Reports, 2015
- SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon RecognitionCancer Cell, 2015
- Trend (1999–2009) in U.S. death rates from myelodysplastic syndromes: Utility of multiple causes of death in surveillanceCancer Epidemiology, 2013
- Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic SyndromeCancer Cell, 2013
- The Spliceosome: Design Principles of a Dynamic RNP MachineCell, 2009